Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics Inc.

Oruka Therapeutics, Inc. ( ($ORKA) ) has released its Q3 earnings. Here is a breakdown of the information Oruka Therapeutics, Inc. presented to its...

Oruka Therapeutics Reports Q3 2025 Financial Results

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intuitive Surgical (ISRG – Research Report) and Oruk...

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Oruka Therapeutics (ORKA)

Barclays analyst Etzer Darout maintained a Buy rating on Oruka Therapeutics today and set a price target of $48.00. Darout covers the Healthcare se...

Current Quarter	$-0.56	Next Quarter	$-0.54
Current Year	$-2.13	Next Year	$-2.44
QoQ Growth	+3.6%	YoY Growth	-14.6%
3Y EPS CAGR	+75.4%	Target Price	$46.90
Consensus	Buy	Upside	+60.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$29.29	+8.52%	397.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORKA	$29.29	+8.5%	397.35K
3
4
5
6

ORKA

ORKA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Oruka Therapeutics Inc. Data in Excel

Get Oruka Therapeutics Inc. Data in Excel